Skip to main
  1. Stocks
  2. Maze Therapeutics Inc
  3. Forecast
MAZE

MAZE Stock Forecast & Price Target

MAZE Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Maze Therapeutics is supported by a diversified, genetics-driven pipeline in CKD and related metabolic disease, with MZE829 offering the most important near-term catalyst through updated HORIZON data in late-2026 and early-2027. The recent VRTX APOL1 readout is viewed as de-risking for MZE829 because it supports proteinuria reduction beyond FSGS and highlights a potential safety edge, while Maze has not reported liver enzyme elevations and notes greater in vitro potency versus inaxaplin. The balance sheet also supports the thesis, with current cash providing runway beyond near-term proof-of-concept readouts, while MZE782 and its Phase 2 CIPheR study add a second shot on goal and a valuation floor ahead of 2027 updates.

Bears say

Maze Therapeutics is vulnerable to fundamental risks that weaken the case for the stock, including regulatory uncertainty, execution risk, and a competitive landscape already populated by branded players such as VRTX and Otsuka alongside generic rivals. The company’s reliance on accelerated approval pathways could still require additional or longer studies, and any failure to secure favorable labels could limit market traction. It is also expected to need additional external funding to advance its platform, so limited access to capital markets could delay or even terminate development campaigns.

MAZE has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

MAZE Analyst Forecast & Price Prediction

Get the latest MAZE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MAZE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Maze Therapeutics Inc (MAZE) Forecast

Analysts have given MAZE a Strong Buy based on their latest research and market trends.

According to 10 analysts, MAZE has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Maze Therapeutics Inc (MAZE)


MAZE Analyst Forecast & Price Prediction

Get the latest MAZE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MAZE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MAZE stock data and trends